These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9883746)

  • 1. Evaluating pathophysiologic processes rather than clinical end points in improving therapeutic practice.
    Cohn JN
    J Cardiovasc Pharmacol; 1998; 32 Suppl 3():S38-40. PubMed ID: 9883746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety in clinical trials in cardiovascular disease.
    Cohn JN
    J Am Coll Cardiol; 2006 Aug; 48(3):430-3. PubMed ID: 16875964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microbiologic surrogate end points in clinical trials of infectious diseases: example of acute otitis media trials.
    Powers JH
    Pharmacotherapy; 2005 Dec; 25(12 Pt 2):109S-123S. PubMed ID: 16305280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mortality trials in cardiovascular medicine.
    Lewis JA
    Cardiology; 1994; 84(6):385-90. PubMed ID: 8062304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unconventional end points in cardiovascular clinical trials: should we be moving away from morbidity and mortality?
    Cohn J; Cleland JG; Lubsen J; Borer JS; Steg PG; Perelman M; Zannad F
    J Card Fail; 2009 Apr; 15(3):199-205. PubMed ID: 19327621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using measures of disease progression to determine therapeutic effect: a sirens' song.
    Granger CB; McMurray JJ
    J Am Coll Cardiol; 2006 Aug; 48(3):434-7. PubMed ID: 16875965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Interactions of cardiac and antiretroviral medication].
    Egger S; Drewe J
    Herz; 2005 Sep; 30(6):493-503. PubMed ID: 16170680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized clinical trials on surrogate end points: are they useful for evaluating cardiovascular and renal disease protection in hypertension? The case for yes.
    Morganti A
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S141-4. PubMed ID: 16565239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational prescribing of statins.
    Purcell H; Daly C; Sheppard M; Morrell J
    Practitioner; 2001 Nov; 245(1628):957-9, 962-3. PubMed ID: 11727350
    [No Abstract]   [Full Text] [Related]  

  • 10. The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases.
    Lonn E
    Pharmacoepidemiol Drug Saf; 2001; 10(6):497-508. PubMed ID: 11828831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers in Alzheimer's disease: not yet surrogate endpoints.
    Coley N; Andrieu S; Delrieu J; Voisin T; Vellas B
    Ann N Y Acad Sci; 2009 Oct; 1180():119-24. PubMed ID: 19906266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of the placebo response and their impact on clinical trials and clinical practice.
    Finniss DG; Benedetti F
    Pain; 2005 Mar; 114(1-2):3-6. PubMed ID: 15733625
    [No Abstract]   [Full Text] [Related]  

  • 13. Biological surrogate end-points in cancer trials: potential uses, benefits and pitfalls.
    Cooper R; Kaanders JH
    Eur J Cancer; 2005 Jun; 41(9):1261-6. PubMed ID: 15939261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs.
    Avouac J; Allanore Y
    Expert Opin Pharmacother; 2008 May; 9(7):1121-8. PubMed ID: 18422470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
    Tang PA; Bentzen SM; Chen EX; Siu LL
    J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why do we need outcomes research in end stage renal disease?
    Nicolucci A; Procaccini DA
    J Nephrol; 2000; 13(6):401-4. PubMed ID: 11132755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evaluation of the results of clinical trials: surrogate end points and composite end points.
    Gensini GF; Conti AA
    Minerva Med; 2004 Feb; 95(1):71-5. PubMed ID: 15041928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice.
    Moore RA; Derry S; Phillips CJ; McQuay HJ
    BMC Musculoskelet Disord; 2006 Oct; 7():79. PubMed ID: 17054784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The gap between reliable evidence and adoption of therapies.
    Yusuf S; Teo KK
    Eur Heart J; 1999 May; 20(9):637-8. PubMed ID: 10419343
    [No Abstract]   [Full Text] [Related]  

  • 20. Surrogate end points in clinical research: hazardous to your health.
    Grimes DA; Schulz KF
    Obstet Gynecol; 2005 May; 105(5 Pt 1):1114-8. PubMed ID: 15863552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.